At a glance
ClinicalIndex Comparison RecordN/ACompleted· 634 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
In Brief
An observational study for Bladder Cancer. Completed, enrolled 634 participants across 1 site.
Detailed Summary
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionOct 2016
Study CompletionNov 2016
TodayJul 2026
First PostedApr 29, 2016
Enrollment StartApr 1, 2016
Primary CompletionOct 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.2 years ago